Accelerating the Genetic Revolution

Neurological Disorders
Muscular Dystrophies
Ocular Diseases
Oncology

A new class of synthetic medicines to address the root cause of genetic diseases

We are at a fundamental inflection point in the history of the pharmaceutical industry where, as a result of the Human Genome Project, we now have the ability to leverage nature’s own information encoding system (the genetic code) to “digitally” encode our drugs so as to target a precise gene that is malfunctioning and neutralize the disease process at its root cause.

As every human disease has genetic drivers, our vision is to dramatically reduce the suffering and death attributable to innumerable diseases across the globe with our first-in-class technology platform.

The therapies we are creating are analogous to heat-seeking missiles in that they are highly specific to only the target gene and promise easy to take and well tolerated medicines.

Technology

The advantages of the NeuBase PATrOL™ platform enable the company to cohesively develop therapies for a wide range of diseases including single-gene disorders, cancers and common diseases

NeuBase is first addressing Huntington’s disease and myotonic dystrophy

Read More

The NeuBase technology has several advantages over other precision genetic medicines

Sd

Scalable & Modular Development

Pre-organized rigid synthetic scaffold increases precision of engagement with target and toolkit of engineered nucleobases allow drugs to be quickly snapped together for many targets

Ts

Targeting Structures

Higher specificity for mutant over wild type genes, allowing for fewer off-target effects and more effective deactivation of disease-causing genes at the DNA and RNA levels

BrOD

Broad Organ Distribution

Modular delivery technologies enable targeting a variety of organ systems

Ni

No Immune Response

Therapies do not cause an immune response when systemically administered, enabling us to develop solutions for pre-symptomatic individuals who are gene mutation positive

NeuBase Therapeutics to Present at the B. Riley Securities’ Virtual Neuroscience Conference

PITTSBURGH, April 27, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview at the B. Riley Securities’ Virtual Neuroscience Conference being held on April 28 - 29.

Read More

NeuBase Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

PITTSBURGH, April 26, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE), (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today the closing of its previously announced underwritten public offering of 9,200,000 shares of its common stock (inclusive of 1,200,000 shares that were sold pursuant to the underwriters’ full exercise of their option to purchase additional shares of NeuBase’s common stock), at a price to the public of $5.00 per share, generating gross proceeds of $46.0 million before deducting the underwriting discounts and commissions and offering expenses payable by NeuBase. NeuBase intends to use the net proceeds from the offering for general corporate purposes, working capital and development of its product candidates and pipeline expansion.

Read More

NeuBase Therapeutics Announces Pricing of $40 Million Public Offering of Common Stock

PITTSBURGH, April 22, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today the pricing of an underwritten public offering of 8,000,000 shares of its common stock, at a price to the public of $5.00 per share. The gross proceeds to NeuBase from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by NeuBase, are expected to be approximately $40 million, excluding any exercise of the underwriters’ option to purchase additional shares of common stock. In addition, NeuBase has granted the underwriters a 30-day option to purchase up to an additional 1,200,000 shares of its common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any. All of the shares of common stock in the offering are being sold by NeuBase.

Read More

NeuBase Therapeutics Announces Proposed Public Offering of Common Stock

PITTSBURGH, April 21, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today that it has commenced an underwritten public offering of shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. In addition, NeuBase intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock sold in the public offering on the same terms and conditions. All of the shares of common stock in the offering will be sold by NeuBase.

Read More

close

Covid-19 Update

Read our statement related to operations during COVID-19